Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Status:
Recruiting
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy
with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.